Sugi Predict

Sugi Predict / Compounds / SCHEMBL15534879

SCHEMBL15534879

SCHEMBL15534879

O=[N+]([O-])c1cc2cn[nH]c2cc1O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOS1 P29475 4/20 0.53
▸ MAPT P10636 3/20 0.53
▸ CYP3A4 P08684 2/20 0.53
▸ ALOX15 P16050 2/20 0.53
▸ LMNA P02545 1/20 0.53
▸ POLB P06746 1/20 0.53
▸ MAOB P27338 1/20 0.53
▸ SMN1; SMN2 Q16637 3/20 0.45
▸ HPGD P15428 2/20 0.45
▸ TSHR P16473 2/20 0.45
▸ HSD17B10 Q99714 2/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ CYP1A2 P05177 1/20 0.45
▸ THRB P10828 1/20 0.45
▸ APEX1 P27695 1/20 0.45
▸ NOS3 P29474 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45
▸ NOS2 P35228 1/20 0.45
▸ RECQL P46063 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28629877 0.93 NOS1 (0.53) NOS1MAPTCYP3A4ALOX15LMNA
SCHEMBL11680975 0.86 MAPT (0.59) NOS1MAPTCYP3A4ALOX15LMNA
SCHEMBL29680531 0.81 NOS1 (0.54) NOS1MAPTCYP3A4ALOX15LMNA
SCHEMBL1026662 0.81 NOS1 (0.54) NOS1MAPTCYP3A4ALOX15LMNA
SCHEMBL16741277 0.80 CHEK1 (0.59) NOS1MAPTCYP3A4ALOX15LMNA
SCHEMBL3769121 0.80 NOS1 (0.53) NOS1MAPTCYP3A4ALOX15LMNA
SCHEMBL2571492 0.80 NOS1 (0.53) NOS1MAPTCYP3A4ALOX15LMNA
SCHEMBL30163112 0.80 NOS1 (0.53) NOS1MAPTCYP3A4ALOX15LMNA
SCHEMBL29680257 0.80 NOS1 (0.53) NOS1MAPTCYP3A4ALOX15LMNA
SCHEMBL16751174 0.80 NOS1 (0.53) NOS1MAPTCYP3A4ALOX15LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12281116-B2 HTT modulators for treating Huntington's disease CHDI FOUNDATION, INC. (US) 2025-04-22 — — US disclosed
WO-2024219864-A1 NOVEL COMPOUND EXHIBITING SETDB1 INHIBITORY ACTIVITY, AND USE THEREOF 주식회사 넷타겟 2024-10-24 — — WO disclosed
EP-4433471-A1 N-(2H-INDAZOL-5-YL)PYRAZINE-2-CARBOXAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS HTT MODULATORS FOR THE TREATMENT OF HUNTINGTON'S DISEASE CHDI Foundation, Inc. (US) 2024-09-25 — — EP disclosed
CN-118510769-A HTT modulators for the treatment of huntington's disease CHDI基金会股份有限公司 2024-08-16 — — CN disclosed
US-20230159531-A1 HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE CHDI FOUNDATION, INC. 2023-05-25 — — US disclosed
WO-2023091456-A1 N-(2H-INDAZOL-5-YL)PYRAZINE-2-CARBOXAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS HTT MODULATORS FOR THE TREATMENT OF HUNTINGTON'S DISEASE CHDI FOUNDATION, INC. (US) 2023-05-25 — — WO disclosed
US-9951086-B2 Indazolecarboxamides, processes for their preparation, pharmaceutical preparations comprising them and their use for producing medicaments BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-04-24 — — US disclosed
EP-3083586-B1 NOVEL CARBOXAMIDES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS COMPRISING THEM, AND USE THEREOF FOR PRODUCING MEDICAMENTS Bayer Pharma AG (DE) 2018-04-18 — — EP disclosed
US-20170107229-A1 SUBSTITUTED TETRAHYDROPYRIDOTHIENOPYRIMIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-04-20 — — US disclosed
US-9540392-B2 Thienopyrimidines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-01-10 — — US disclosed
EP-2852596-B1 THIENOPYRIMIDINES Bayer Pharma AG (DE) 2016-06-22 — — EP disclosed
WO-2015181063-A1 SUBSTITUTED TETRAHYDROPYRIDOTHIENOPYRIMIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-12-03 — — WO disclosed
WO-2015091426-A1 NOVEL CARBOXAMIDES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS COMPRISING THEM, AND USE THEREOF FOR PRODUCING MEDICAMENTS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-06-25 — — WO disclosed
WO-2015074986-A1 THIENOPYRIMIDINES AS MKNK1 AND MKNK2 INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-05-28 — — WO disclosed
WO-2015074986-A1 THIENOPYRIMIDINES AS MKNK1 AND MKNK2 INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-05-28 — — WO disclosed
US-20150133425-A1 THIENOPYRIMIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-05-14 — — US disclosed
US-20150133425-A1 THIENOPYRIMIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-05-14 — — US disclosed
CN-104507950-A Thienopyrimidines Bayer Pharma AG 2015-04-08 — — CN disclosed
EP-2852596-A1 THIENOPYRIMIDINES Bayer Pharma Aktiengesellschaft (DE) 2015-04-01 — — EP disclosed
WO-2013174744-A1 THIENOPYRIMIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2013-11-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12281116-B2 HTT modulators for treating Huntington's disease HTT, HYPK, ATXN2 NOS1 4708/4885MAPT 76/4885CYP3A4 4809/4885
US-20230159531-A1 HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE HTT, HYPK, ATXN2 NOS1 4708/4885MAPT 76/4885CYP3A4 4809/4885
US-20150133425-A1 THIENOPYRIMIDINES TYMP, DPYD, TYMS NOS1 1212/4885MAPT 2275/4885CYP3A4 832/4885
US-20170107229-A1 SUBSTITUTED TETRAHYDROPYRIDOTHIENOPYRIMIDINES TYMP, DPYD, TYMS NOS1 1007/4885MAPT 2227/4885CYP3A4 1158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.